New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif GSK joins AstraZeneca and Labcyte to develop acoustic mass spectrometry http://www.pharmaceutical-technology.com/news/newsgsk-joins-astrazeneca-to-use-labcytes-acoustic-technology-to-develop-mass-spectrometry-5931620 http://www.pharmaceutical-technology.com/news/newsgsk-joins-astrazeneca-to-use-labcytes-acoustic-technology-to-develop-mass-spectrometry-5931620 GSK has joined forces with AstraZeneca and Labcyte to combine acoustic liquid dispensing technology with mass spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications. Thu, 21 Sep 2017 23:00:00 GMT Deals this week: Aspen Global Incorporated, Zhejiang Conba Pharmaceutical, Teva Pharmaceutical Industries http://www.pharmaceutical-technology.com/news/newsdeals-this-week-aspen-global-incorporated-zhejiang-conba-pharmaceutical-teva-pharmaceutical-industries-5930775 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-aspen-global-incorporated-zhejiang-conba-pharmaceutical-teva-pharmaceutical-industries-5930775 Mauritius-based holding company Aspen Global Incorporated (AGI) has signed an agreement with AstraZeneca to acquire the rights to the latter’s anaesthetic treatments portfolio for $555m. Thu, 21 Sep 2017 23:00:00 GMT Novartis’ Rydapt receives approval for two cancer treatments in the EU http://www.pharmaceutical-technology.com/news/newsnovartis-rydapt-receives-approval-for-two-cancer-treatments-in-the-eu-5931569 http://www.pharmaceutical-technology.com/news/newsnovartis-rydapt-receives-approval-for-two-cancer-treatments-in-the-eu-5931569 The European Commission (EC) has approved Novartis’ Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Thu, 21 Sep 2017 23:00:00 GMT M&As this week: Catalent, Ultragenyx Pharmaceutical http://www.pharmaceutical-technology.com/news/newsmas-this-week-catalent-ultragenyx-pharmaceutical-5930779 http://www.pharmaceutical-technology.com/news/newsmas-this-week-catalent-ultragenyx-pharmaceutical-5930779 Catalent has announced plans to acquire Cook Pharmica for $950m. Thu, 21 Sep 2017 23:00:00 GMT Recipharm and Roche sign agreement to manufacture solid dose products http://www.pharmaceutical-technology.com/news/newsrecipharm-roche-sign-agreement-to-manufacture-solid-dose-products-5930718 http://www.pharmaceutical-technology.com/news/newsrecipharm-roche-sign-agreement-to-manufacture-solid-dose-products-5930718 Swedish pharmaceutical company Recipharm has signed a long-term manufacturing agreement with Roche to produce a wide range of solid dose products. Wed, 20 Sep 2017 23:00:00 GMT Pfizer files lawsuit against J&J’s exclusionary contracts for Remicade http://www.pharmaceutical-technology.com/news/newspfizer-files-suit-against-johnson-johnson-for-healthy-biologics-competition-5930952 http://www.pharmaceutical-technology.com/news/newspfizer-files-suit-against-johnson-johnson-for-healthy-biologics-competition-5930952 Pfizer has filed a lawsuit against Johnson & Johnson (J&J) in the US District Court for the Eastern District of Pennsylvania to ensure patients and providers have access to major, lower-cost biosimilar therapies. Wed, 20 Sep 2017 23:00:00 GMT NICE recommends Bristol-Myers Squibb’s nivolumab for NSCLC patients on NHS http://www.pharmaceutical-technology.com/news/newsnice-recommends-bristol-myers-squibbs-nivolumab-for-nsclc-patients-on-nhs-5930408 http://www.pharmaceutical-technology.com/news/newsnice-recommends-bristol-myers-squibbs-nivolumab-for-nsclc-patients-on-nhs-5930408 The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol-Myers Squibb’s immunotherapy drug Opdivo (nivolumab) for NHS use through the Cancer Drugs Fund (CDF) for the treatment of advanced non-small-cell lung cancer (NSC… Wed, 20 Sep 2017 23:00:00 GMT Zydus and Pharm Aid enter deal for varicella vaccine technology in Russia http://www.pharmaceutical-technology.com/news/newszydus-pharm-aid-enter-into-deal-for-varicella-vaccine-technology-in-russia-5929528 http://www.pharmaceutical-technology.com/news/newszydus-pharm-aid-enter-into-deal-for-varicella-vaccine-technology-in-russia-5929528 Indian healthcare company Zydus Cadila has entered an exclusive agreement with Pharm Aid for the technology expertise of varicella vaccine production in Russia to prevent chickenpox. Tue, 19 Sep 2017 23:00:00 GMT Catalent signs agreement to buy Cook Pharmica for $950m http://www.pharmaceutical-technology.com/news/newscook-group-signs-agreement-to-sell-cook-pharmica-to-catalent-for-950m-5929790 http://www.pharmaceutical-technology.com/news/newscook-group-signs-agreement-to-sell-cook-pharmica-to-catalent-for-950m-5929790 US-based company Cook Group has reached an agreement to divest its drug manufacturing division Cook Pharmica to Catalent for $950m. Tue, 19 Sep 2017 23:00:00 GMT New study suggests jet lag drug benefits patients undergoing chemotherapy http://www.pharmaceutical-technology.com/news/newsnew-study-suggests-jet-lag-drug-benefits-patients-undergoing-chemotherapy-5930008 http://www.pharmaceutical-technology.com/news/newsnew-study-suggests-jet-lag-drug-benefits-patients-undergoing-chemotherapy-5930008 A recent study conducted by scientists at the Universities of Edinburgh and Aberdeen has suggested that painful side effects from cancer medicines can be managed using melatonin, a drug that helps ease the effects of jet lag. Tue, 19 Sep 2017 23:00:00 GMT Teva to sell assets in global women’s health business for $1.38bn http://www.pharmaceutical-technology.com/news/newsteva-pharmaceutical-to-sell-assets-in-global-womens-health-business-for-138bn-5928713 http://www.pharmaceutical-technology.com/news/newsteva-pharmaceutical-to-sell-assets-in-global-womens-health-business-for-138bn-5928713 Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for $1.38bn. Mon, 18 Sep 2017 23:00:00 GMT NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells http://www.pharmaceutical-technology.com/news/newsnus-study-shows-artemisinin-ala-co-treatment-can-combat-cancer-cells-5928640 http://www.pharmaceutical-technology.com/news/newsnus-study-shows-artemisinin-ala-co-treatment-can-combat-cancer-cells-5928640 A new study conducted by researchers from the National University of Singapore (NUS) has revealed that the co-treatment using artemisinin and aminolaevulinic acid (ALA) can potentially kill cancer cells and suppress tumour growth with fewer side effe… Mon, 18 Sep 2017 23:00:00 GMT Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases http://www.pharmaceutical-technology.com/news/newsimmunocore-receives-funding-to-develop-immtav-and-immtab-therapeutics-for-infectious-diseases-5927937 http://www.pharmaceutical-technology.com/news/newsimmunocore-receives-funding-to-develop-immtav-and-immtab-therapeutics-for-infectious-diseases-5927937 Immunocore has secured up to $40m in investment from Bill & Melinda Gates Foundation to boost the development of soluble T-cell receptor (TCR)-based therapeutics to treat infectious diseases, in particular tuberculosis (TB) and human immunodeficiency… Mon, 18 Sep 2017 23:00:00 GMT Amgen and Allergan’s anti-cancer biosimilar Mvasi receives FDA approval http://www.pharmaceutical-technology.com/news/newsfda-grants-approval-for-mvasi-to-treat-five-types-of-cancer-5927061 http://www.pharmaceutical-technology.com/news/newsfda-grants-approval-for-mvasi-to-treat-five-types-of-cancer-5927061 The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. Sun, 17 Sep 2017 23:00:00 GMT GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD http://www.pharmaceutical-technology.com/news/newsgsk-innoviva-receive-positive-opinion-from-chmp-for-trelegy-ellipta-to-treat-copd-5927589 http://www.pharmaceutical-technology.com/news/newsgsk-innoviva-receive-positive-opinion-from-chmp-for-trelegy-ellipta-to-treat-copd-5927589 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing authorisation of Trelegy Ellipta as a maintenance treatment in adult patients with moderate-to-severe chronic obst… Sun, 17 Sep 2017 23:00:00 GMT Aspen to acquire remaining rights to AstraZeneca’s anaesthetic medicines http://www.pharmaceutical-technology.com/news/newsaspen-enter-into-agreement-to-exercise-remaining-rights-for-astrazenecas-anaesthetic-therapies-5926963 http://www.pharmaceutical-technology.com/news/newsaspen-enter-into-agreement-to-exercise-remaining-rights-for-astrazenecas-anaesthetic-therapies-5926963 Aspen Global Incorporated (AGI) has entered an agreement to acquire all the remaining rights to AstraZeneca’s established anaesthetic treatments for an upfront consideration of $555m. Sun, 17 Sep 2017 23:00:00 GMT Evotec and MaRS Innovation launch new drug-discovery partnership http://www.pharmaceutical-technology.com/news/newsevotec-and-mars-innovation-launch-new-drug-discovery-partnership-5926127 http://www.pharmaceutical-technology.com/news/newsevotec-and-mars-innovation-launch-new-drug-discovery-partnership-5926127 German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario, Canada. Thu, 14 Sep 2017 23:00:00 GMT Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals http://www.pharmaceutical-technology.com/news/newsdeals-this-week-pivot-pharmaceuticals-innovation-pharmaceuticals-portola-pharmaceuticals-5925363 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-pivot-pharmaceuticals-innovation-pharmaceuticals-portola-pharmaceuticals-5925363 Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology. Thu, 14 Sep 2017 23:00:00 GMT M&As this week: Silver Falcon, Adcock Ingram Holdings, Boya Bio-pharmaceutical Group http://www.pharmaceutical-technology.com/news/newsmas-this-week-silver-falcon-plc-adcock-ingram-holdings-boya-bio-pharmaceutical-group-5925367 http://www.pharmaceutical-technology.com/news/newsmas-this-week-silver-falcon-plc-adcock-ingram-holdings-boya-bio-pharmaceutical-group-5925367 Financial services provider Silver Falcon plans to acquire biotechnology company Hemogenyx Pharmaceuticals (Hemogenyx Pharma) for £8m ($10.5m). Thu, 14 Sep 2017 23:00:00 GMT Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs http://www.pharmaceutical-technology.com/news/newsbristol-myers-squibb-to-use-halozymes-technology-to-develop-immuno-oncology-drugs-5926083 http://www.pharmaceutical-technology.com/news/newsbristol-myers-squibb-to-use-halozymes-technology-to-develop-immuno-oncology-drugs-5926083 Bristol-Myers Squibb has entered a global collaboration and licence agreement to use Halozyme Therapeutics’ Enhanze drug-delivery technology for the development of its subcutaneously administered immuno-oncology treatments. Thu, 14 Sep 2017 23:00:00 GMT